Skip to content
lifestyle.luxedb.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kymera Therapeutics, Inc.
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
July 7, 2026
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
June 25, 2026
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
June 24, 2026
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
June 12, 2026
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
May 15, 2026
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
May 6, 2026
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
May 5, 2026
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 30, 2026
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
April 23, 2026
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
April 13, 2026
1
2
Next Page
→